Nevro (NVRO)
(Real Time Quote from BATS)
$5.81 USD
-0.04 (-0.68%)
Updated Sep 20, 2024 03:49 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Company Summary
Headquartered in Menlo Park, CA, Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza SCS system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company’s HF10 therapy provides long-lasting relief from chronic back and leg pain.
Nevro’s flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, ...
Company Summary
Headquartered in Menlo Park, CA, Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza SCS system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company’s HF10 therapy provides long-lasting relief from chronic back and leg pain.
Nevro’s flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011. In early 2017, Nevro commenced a controlled commercial launch of a new surgical lead, marketed as the Surpass TM surgical lead.
The company has developed and commercialized our HFX SCS platform, which includes the Senza SCS system, with the Senza HFX iQ platform being its latest addition to the Senza family of products. The HFX solution is approved to deliver a versatile range of waveforms, including our proprietary, paresthesia-free 10 kHz Therapy.
In recent times, Nevro launched its next product platform, Senza Omnia, in the United States which is expected to lend the company a competitive edge in the near future.
The company also has bright prospects when it comes to other chronic pain indications where it uses HF10 therapy to treat chronic upper limb and neck pain and other non-surgical back pain (NSBP).
General Information
Nevro Corp
1800 BRIDGE PARKWAY
REDWOOD CITY, CA 94065
Phone: 650-251-0005
Fax: NA
Web: http://www.nevro.com
Email: ir@nevro.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/6/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.82 |
Current Year EPS Consensus Estimate | -2.69 |
Estimated Long-Term EPS Growth Rate | 18.60 |
Exp Earnings Date | 11/6/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 5.85 |
52 Week High | 22.64 |
52 Week Low | 4.38 |
Beta | 0.94 |
20 Day Moving Average | 504,582.41 |
Target Price Consensus | 9.99 |
4 Week | 8.94 |
12 Week | -30.02 |
YTD | -72.82 |
4 Week | 6.21 |
12 Week | -32.85 |
YTD | -77.31 |
Shares Outstanding (millions) | 37.28 |
Market Capitalization (millions) | 218.11 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 37.68% |
vs. Previous Quarter | 38.57% |
vs. Previous Year | -4.27% |
vs. Previous Quarter | 2.22% |
Price/Book | 0.78 |
Price/Cash Flow | NA |
Price / Sales | 0.51 |
6/30/24 | -24.89 |
3/31/24 | -27.48 |
12/31/23 | -30.22 |
6/30/24 | -11.75 |
3/31/24 | -13.40 |
12/31/23 | -15.17 |
6/30/24 | 4.77 |
3/31/24 | 7.38 |
12/31/23 | 6.37 |
6/30/24 | 3.53 |
3/31/24 | 5.57 |
12/31/23 | 4.94 |
6/30/24 | -16.53 |
3/31/24 | -18.37 |
12/31/23 | -20.88 |
6/30/24 | -18.17 |
3/31/24 | -19.17 |
12/31/23 | -21.69 |
6/30/24 | -19.54 |
3/31/24 | -20.47 |
12/31/23 | -23.02 |
6/30/24 | 7.47 |
3/31/24 | 7.59 |
12/31/23 | 8.10 |
6/30/24 | 1.12 |
3/31/24 | 1.11 |
12/31/23 | 1.14 |
6/30/24 | 0.66 |
3/31/24 | 0.77 |
12/31/23 | 0.72 |
6/30/24 | 39.70 |
3/31/24 | 43.54 |
12/31/23 | 41.91 |